Generic Fosamax Users Must Give More Details In MDL
Law360, New York (December 19, 2013, 8:04 PM EST) -- A New York federal judge on Wednesday ordered plaintiffs in multidistrict litigation against Teva Pharmaceuticals USA Inc. to divulge when they had taken a generic version of the bone drug Fosamax, in order to back the claim that Teva's failure to update the drug's labeling had led to their jaw injuries.
The ruling came in response to Teva's motion for a more definite statement following U.S. District Judge John Keenan's August decision that all of the claims against Teva were preempted except so-called failure-to-update allegations.
Those claims would hold that Teva failed to warn users of the risks of generic Fosamax,...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!